https://andards.com/tags/longevity-biotech/ Recent content in longevity-biotech on AndArds Hugo -- gohugo.io en-us Thu, 09 Apr 2026 23:57:00 +0000 https://andards.com/posts/juan-carlos-izpisua-belmonte-and-the-race-for-in-vivo-reprogramming/ Thu, 09 Apr 2026 23:57:00 +0000 https://andards.com/posts/juan-carlos-izpisua-belmonte-and-the-race-for-in-vivo-reprogramming/ In vivo cellular reprogramming represents a frontier in biological research, aiming to reset cellular clocks or alter cell identities directly within a living organism. This field holds significant promise for regenerative medicine and addressing age-related conditions. Dr. https://andards.com/posts/ai-and-gene-editing-the-next-decade-of-longevity-biotech/ Sun, 05 Apr 2026 00:33:00 +0000 https://andards.com/posts/ai-and-gene-editing-the-next-decade-of-longevity-biotech/ The quest to extend healthy human lifespan is undergoing a transformation, propelled by the convergence of artificial intelligence (AI) and gene editing technologies. Over the next decade, these fields are poised to redefine what’s possible in longevity biotech, moving beyond theoretical discussions to tangible, therapeutic interventions. https://andards.com/posts/senolytics-vs.-senomorphics-whats-the-difference-in-longevity-biotech/ Fri, 03 Apr 2026 22:07:00 +0000 https://andards.com/posts/senolytics-vs.-senomorphics-whats-the-difference-in-longevity-biotech/ The pursuit of healthy aging has led to significant advancements in understanding cellular processes. Among these, the study of cellular senescence – a state where cells stop dividing but remain metabolically active, often releasing inflammatory signals – has opened new avenues for therapeutic intervention. https://andards.com/posts/laura-demings-longevity-fund-the-startups-trying-to-cure-aging/ Sun, 29 Mar 2026 02:01:00 +0000 https://andards.com/posts/laura-demings-longevity-fund-the-startups-trying-to-cure-aging/ The idea of “curing aging” might sound like science fiction, but a growing number of scientists, entrepreneurs, and investors are dedicating significant resources to making it a reality. At the forefront of this effort is Laura Deming, whose Longevity Fund has become a pivotal force in identifying and backing early-stage companies focused on extending healthy human lifespan. https://andards.com/posts/senolytics-vs.-cellular-reprogramming-which-approach-will-cure-aging-first/ Fri, 20 Mar 2026 23:46:00 +0000 https://andards.com/posts/senolytics-vs.-cellular-reprogramming-which-approach-will-cure-aging-first/ The quest to understand and mitigate aging has led to two particularly promising, yet distinct, biotechnological strategies: senolytics and cellular reprogramming. Both aim to address fundamental aspects of the aging process, but they do so through different mechanisms, offering unique advantages and challenges. https://andards.com/posts/the-longevity-industry-the-investors-and-mavericks-funding-the-future/ Wed, 18 Mar 2026 20:34:00 +0000 https://andards.com/posts/the-longevity-industry-the-investors-and-mavericks-funding-the-future/ The longevity industry, a rapidly expanding sector focused on extending healthy human lifespan, is attracting significant investment. This isn’t merely about prolonging existence, but enhancing “healthspan” – the period of life spent in good health. The field encompasses diverse areas, from regenerative medicine and novel therapeutics to artificial intelligence applications and personalized nutrition. https://andards.com/posts/laura-demings-longevity-fund-what-are-they-actually-investing-in/ Fri, 13 Mar 2026 23:30:00 +0000 https://andards.com/posts/laura-demings-longevity-fund-what-are-they-actually-investing-in/ Laura Deming’s Longevity Fund is a venture capital firm focused on companies developing technologies to extend healthy human lifespan. Since its inception, the fund has backed a range of early-stage biotechnology startups, aiming to translate fundamental research into therapeutic interventions. https://andards.com/posts/alex-zhavoronkov-and-insilico-medicine-ais-role-in-curing-aging/ Sun, 22 Feb 2026 18:53:00 +0000 https://andards.com/posts/alex-zhavoronkov-and-insilico-medicine-ais-role-in-curing-aging/ Alex Zhavoronkov and Insilico Medicine are at the forefront of a movement aiming to revolutionize drug discovery and extend healthy human lifespan using artificial intelligence. Their work centers on the idea that aging is a treatable disease, and that AI can dramatically accelerate the process of identifying and developing therapies to address it. https://andards.com/posts/alex-zhavoronkov-and-insilico-medicine-how-ai-is-discovering-longevity-drugs/ Wed, 18 Feb 2026 02:49:00 +0000 https://andards.com/posts/alex-zhavoronkov-and-insilico-medicine-how-ai-is-discovering-longevity-drugs/ The quest for extending healthy human lifespan, often termed longevity, has long been a subject of science fiction. Today, it’s a rapidly evolving field of scientific inquiry, with artificial intelligence (AI) emerging as a crucial tool. At the forefront of this intersection is Alex Zhavoronkov, CEO of Insilico Medicine. https://andards.com/posts/sebastian-brunemeier-and-the-rise-of-longevity-venture-capital/ Wed, 18 Feb 2026 00:46:00 +0000 https://andards.com/posts/sebastian-brunemeier-and-the-rise-of-longevity-venture-capital/ Sebastian Brunemeier is a figure at the intersection of biotechnology and finance, known for his work in the longevity venture capital space. His involvement with entities like Healthspan Capital and LongGame Ventures highlights a growing trend: the focused investment in companies aiming to extend human healthspan, not just lifespan. https://andards.com/posts/altos-labs-and-the-billionaire-race-to-cure-aging/ Sun, 18 Jan 2026 07:19:00 +0000 https://andards.com/posts/altos-labs-and-the-billionaire-race-to-cure-aging/ Altos Labs has emerged as a significant player in the burgeoning field of longevity research, attracting substantial investment from high-profile individuals, most notably Jeff Bezos. This cellular rejuvenation startup is focused on understanding and potentially reversing the processes of aging at a fundamental biological level, aiming to extend healthy human lifespan. https://andards.com/posts/sebastian-brunemeier-and-healthspan-capital-investing-in-longevity-biotech/ Sun, 18 Jan 2026 06:12:00 +0000 https://andards.com/posts/sebastian-brunemeier-and-healthspan-capital-investing-in-longevity-biotech/ Sebastian Brunemeier stands out in the burgeoning field of longevity biotech investment. Through Healthspan Capital and other ventures, he focuses on identifying and nurturing companies that aim to extend not just lifespan, but also “healthspan” — the period of life spent in good health. https://andards.com/posts/the-biotech-vanguard-the-scientists-reprogramming-human-cells/ Thu, 01 Jan 2026 01:20:00 +0000 https://andards.com/posts/the-biotech-vanguard-the-scientists-reprogramming-human-cells/ The pursuit of understanding and influencing human aging has moved beyond traditional medicine into the realm of biotechnology, specifically cellular reprogramming. This field, driven by dedicated longevity biotech scientists, aims to manipulate biological processes at a fundamental level – the cell itself – to extend healthy lifespan.